Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;43(10):1043-1050.
doi: 10.1002/phar.2850. Epub 2023 Aug 14.

Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium

Erin K McCreary  1 , Matthew R Davis  2 , Navaneeth Narayanan  3 , David R Andes  4 , Dario Cattaneo  5 , Robbie Christian  6 , Russell E Lewis  7 , Kevin M Watt  8 , Nathan P Wiederhold  9 , Melissa D Johnson  10
Affiliations
Review

Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium

Erin K McCreary et al. Pharmacotherapy. 2023 Oct.

Abstract

Triazole antifungals (i.e., fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) are commonly used in clinical practice to prevent or treat invasive fungal infections. Most triazole antifungals require therapeutic drug monitoring (TDM) due to highly variable pharmacokinetics, known drug interactions, and established relationships between exposure and response. On behalf of the Society of Infectious Diseases Pharmacists (SIDP), this insight describes the pharmacokinetic principles and pharmacodynamic targets of commonly used triazole antifungals and provides the rationale for utility of TDM within each agent.

Keywords: fluconazole; isavuconazole; itraconazole; pharmacodynamics; pharmacokinetics; posaconazole; voriconazole.

PubMed Disclaimer

References

REFERENCES

    1. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-National Prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57. doi:10.3390/jof3040057
    1. Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis. 2022;9(1):ofab593. doi:10.1093/ofid/ofab593
    1. Ostrosky-Zeichner L, Nguyen MH, Bubalo J, et al. Multicenter registry of patients receiving systemic Mold-active triazoles for the Management of Invasive Fungal Infections. Infect Dis Ther. 2022;11(4):1609-1629. doi:10.1007/s40121-022-00661-5
    1. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080-1087. doi:10.1093/cid/cis599
    1. Lindsay J, Krantz EM, Morris J, et al. Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center. Transplant Cell Ther. 2022;28(8):511. doi:10.1016/j.jtct.2022.05.030

LinkOut - more resources